65 related articles for article (PubMed ID: 20825494)
1. Purvalanol A, a CDK inhibitor, effectively suppresses Src-mediated transformation by inhibiting both CDKs and c-Src.
Hikita T; Oneyama C; Okada M
Genes Cells; 2010 Oct; 15(10):1051-62. PubMed ID: 20825494
[TBL] [Abstract][Full Text] [Related]
2. The pro-apoptotic protein Prostate Apoptosis Response Protein-4 (Par-4) can be activated in colon cancer cells by treatment with Src inhibitor and 5-FU.
Kline CL; Irby RB
Apoptosis; 2011 Dec; 16(12):1285-94. PubMed ID: 21910008
[TBL] [Abstract][Full Text] [Related]
3. Purvalanol A enhances cell killing by inhibiting up-regulation of CDC2 kinase activity in tumor cells irradiated with high doses of X rays.
Iizuka D; Inanami O; Kashiwakura I; Kuwabara M
Radiat Res; 2007 May; 167(5):563-71. PubMed ID: 17474786
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of autophagy by 3-MA potentiates purvalanol-induced apoptosis in Bax deficient HCT 116 colon cancer cells.
Coker-Gurkan A; Arisan ED; Obakan P; Guvenir E; Unsal NP
Exp Cell Res; 2014 Oct; 328(1):87-98. PubMed ID: 25088259
[TBL] [Abstract][Full Text] [Related]
5. Csk-binding protein (Cbp) negatively regulates epidermal growth factor-induced cell transformation by controlling Src activation.
Jiang LQ; Feng X; Zhou W; Knyazev PG; Ullrich A; Chen Z
Oncogene; 2006 Sep; 25(40):5495-506. PubMed ID: 16636672
[TBL] [Abstract][Full Text] [Related]
6. The transmembrane adaptor Cbp/PAG1 controls the malignant potential of human non-small cell lung cancers that have c-src upregulation.
Kanou T; Oneyama C; Kawahara K; Okimura A; Ohta M; Ikeda N; Shintani Y; Okumura M; Okada M
Mol Cancer Res; 2011 Jan; 9(1):103-14. PubMed ID: 21156787
[TBL] [Abstract][Full Text] [Related]
7. Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells.
Yenugonda VM; Deb TB; Grindrod SC; Dakshanamurthy S; Yang Y; Paige M; Brown ML
Bioorg Med Chem; 2011 Apr; 19(8):2714-25. PubMed ID: 21440449
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of the tumor suppressor gene C-terminal Src kinase: an early event during premalignant colonic epithelial hyperproliferation.
Kunte DP; Wali RK; Koetsier JL; Hart J; Kostjukova MN; Kilimnik AY; Pyatkin IG; Strelnikova SR; Roy HK
FEBS Lett; 2005 Jul; 579(17):3497-502. PubMed ID: 15961079
[TBL] [Abstract][Full Text] [Related]
9. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models.
Golas JM; Lucas J; Etienne C; Golas J; Discafani C; Sridharan L; Boghaert E; Arndt K; Ye F; Boschelli DH; Li F; Titsch C; Huselton C; Chaudhary I; Boschelli F
Cancer Res; 2005 Jun; 65(12):5358-64. PubMed ID: 15958584
[TBL] [Abstract][Full Text] [Related]
10. p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol.
Knockaert M; Lenormand P; Gray N; Schultz P; Pouysségur J; Meijer L
Oncogene; 2002 Sep; 21(42):6413-24. PubMed ID: 12226745
[TBL] [Abstract][Full Text] [Related]
11. Albumin-induced epithelial-mesenchymal transition and ER stress are regulated through a common ROS-c-Src kinase-mTOR pathway: effect of imatinib mesylate.
Lee JY; Chang JW; Yang WS; Kim SB; Park SK; Park JS; Lee SK
Am J Physiol Renal Physiol; 2011 May; 300(5):F1214-22. PubMed ID: 21367918
[TBL] [Abstract][Full Text] [Related]
12. Glucose 6-phosphate dehydrogenase is regulated through c-Src-mediated tyrosine phosphorylation in endothelial cells.
Pan S; World CJ; Kovacs CJ; Berk BC
Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):895-901. PubMed ID: 19359662
[TBL] [Abstract][Full Text] [Related]
13. Activation of c-Src/HER1/STAT5b and HER1/ERK1/2 signaling pathways and cell migration by hexachlorobenzene in MDA-MB-231 human breast cancer cell line.
Pontillo CA; García MA; Peña D; Cocca C; Chiappini F; Alvarez L; Kleiman de Pisarev D; Randi AS
Toxicol Sci; 2011 Apr; 120(2):284-96. PubMed ID: 21205633
[TBL] [Abstract][Full Text] [Related]
14. Raf-1 kinase activation is uncoupled from downstream MEK/ERK pathway in cells treated with Src tyrosine kinase inhibitor PP2.
Lee M
Biochem Biophys Res Commun; 2006 Nov; 350(2):450-6. PubMed ID: 17010316
[TBL] [Abstract][Full Text] [Related]
15. Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation.
Darmoul D; Gratio V; Devaud H; Peiretti F; Laburthe M
Mol Cancer Res; 2004 Sep; 2(9):514-22. PubMed ID: 15383630
[TBL] [Abstract][Full Text] [Related]
16. Functional dissection of transformation by c-Src and v-Src.
Oneyama C; Hikita T; Nada S; Okada M
Genes Cells; 2008 Jan; 13(1):1-12. PubMed ID: 18173743
[TBL] [Abstract][Full Text] [Related]
17. Activation of MAP kinase by muscarinic cholinergic receptors induces cell proliferation and protein synthesis in human breast cancer cells.
Jiménez E; Montiel M
J Cell Physiol; 2005 Aug; 204(2):678-86. PubMed ID: 15744749
[TBL] [Abstract][Full Text] [Related]
18. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors.
Tan M; Li P; Sun M; Yin G; Yu D
Oncogene; 2006 Jun; 25(23):3286-95. PubMed ID: 16407820
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.
Moasser MM; Srethapakdi M; Sachar KS; Kraker AJ; Rosen N
Cancer Res; 1999 Dec; 59(24):6145-52. PubMed ID: 10626805
[TBL] [Abstract][Full Text] [Related]
20. The lipid raft-anchored adaptor protein Cbp controls the oncogenic potential of c-Src.
Oneyama C; Hikita T; Enya K; Dobenecker MW; Saito K; Nada S; Tarakhovsky A; Okada M
Mol Cell; 2008 May; 30(4):426-36. PubMed ID: 18498747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
